GlassScriptPhysician profile
Penelope Velasco
NPI 1124189576
$732.84
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $28.05 · 2021: $17.23 · 2022: $20.23 · 2023: $101 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $260.89 | 2019 | |
| Intuitive Surgical, INC. | $100.80 | 2023 | Da Vinci Surgical System |
| Mayne Pharma Commercial LLC | $64.69 | 2025 | |
| Organon LLC | $60.90 | 2021-2025 | Nexplanon |
| Sage Therapeutics, LLC | $34.16 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $32.42 | 2019 | |
| Sumitomo Pharma America, INC. | $31.83 | 2025 | Myfembree |
| Cranial Technologies, INC | $26.91 | 2019-2020 | |
| Shield Therapeutics INC | $24.96 | 2025 | |
| Astellas Pharma US INC | $24.37 | 2025 | Veozah |
| Amag Pharmaceuticals, INC. | $19.72 | 2019 | |
| Exeltis, USA INC. | $18.99 | 2025 | Slynd |
| Aspira Women'S Health INC | $18.52 | 2025 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penelope Velasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.